PACOCF3 Property

Boiling point:

329.0±37.0 °C(Predicted)

Density 

0.955±0.06 g/cm3(Predicted)

RTECS 

MI3927000

Flash point:

14℃

storage temp. 

−20°C

solubility 

Soluble in DMSO

form 

Liquid

color 

White to off-white

Safety

Hazard Codes 

Xi,F

Risk Statements 

36/37/38-11

Safety Statements 

26-36-16

RIDADR 

UN1170 - class 3 - PG 2 - Ethanol, solution

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P308+P313IF exposed or concerned: Get medical advice/attention.

PACOCF3 Chemical Properties,Usage,Production

Description

PTK is an analog of palmitic acid in which the COOH group is replaced by trifluoromethyl ketone. In P388D1 cells, PTK inhibits iPLA₂ activity with an IC₅₀ value of 3.8 μM. A related compound, ATK is a less potent inhibitor of iPLA₂ with an IC₅₀ value of 15 μM. PTK also inhibits the activity of cPLA₂ with an IC₅₀ value almost identical to that of ATK.

Uses

PACOCF3 is an inductors of BLM, an artificial lipid membranes and liposome permeabilization. Phospholipase A2 inhibitor.

Definition

ChEBI: Palmityl Trifluoromethyl Ketone is an alpha-haloketone.

Biological Activity

Phospholipase A 2 inhibitor. Can also alter Ca 2+ signaling in renal tubular cells.

References

1. murakami m et al.emerging roles of secreted phospholipase a2 enzymes: the 3rd edition.biochimie. 2014 sep 16. pii: s0300-9084(14)00252-1.2. quach nd et al. secretory phospholipase a2 enzymes as pharmacological targets for treatment of disease. biochem pharmacol. 2014 aug 15;90(4):338-48. 3. chalimoniuk m. secretory phospholipase a2 and its role in oxidative stress and inflammation]. postepy biochem. 2012;58(2):204-8.4. persaud sj.et al. the role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans. diabetes. 2007 jan;56(1):197-203.5. khakpour h et al. lipoprotein-associated phospholipase a2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. cardiol rev. 2009 sep-oct;17(5):222-9. 6. narendra sharath chandra jn1 et al. chemistry and structural evaluation of different phospholipase a2 inhibitors in arachidonic acid pathway mediated inflammation and snake venom toxicity. curr top med chem. 2007;7(8):787-800.7. packard cj. lipoprotein-associated phospholipase a2 as a biomarker of coronary heart disease and a therapeutic target. curr opin cardiol. 2009 jul;24(4):358-63.8. lucas r et al. synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases a2. bioorg med chem lett. 2000 feb 7;10(3):285-8.